Spero strikes $125M royalty deal for cUTI drug; French firm launches $100M early biotech fund
French investment firm Advent France Biotechnology (AFB) announced today the first closing of its second fund for a total of $102 million.
Investors and participants in AFB’s fund included the European Investment Fund (EIF) and the Fonds national d’amorçage 2 (the French Seed Fund 2), which is managed on behalf of the French State by Bpifrance. Other participants included corporate venture funds such as Boehringer Ingelheim’s venture fund.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.